361 Capital’s Avanos Medical AVNS Stock Holding History

361 Capital’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-40,300	Closed	-$1.81M	–	235
2017 Q3	$1.81M	Buy	+40,300	New	+$1.72M	0.35%	159

Other funds holding AVNS

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

361 Capital's AVNS Position: Q4 2017 in Review

361 Capital sold out of Avanos Medical (AVNS) in Q4 2017, closing a stake of 40,300 shares — an estimated $1.81M sold.

361 Capital first reported a position in AVNS in Q3 2017 and held it in 1 quarter. The position peaked at $1.81M in Q3 2017. 350 funds tracked by Wall St. Rank hold AVNS as of Q4 2017.

361 Capital reported no remaining Avanos Medical position as of Q4 2017 after selling out during the quarter.
361 Capital sold 40,300 Avanos Medical shares in Q4 2017, an estimated $1.81M.
361 Capital first reported a position in Avanos Medical in Q3 2017 and held it in 1 quarter.
361 Capital's Avanos Medical position peaked at $1.81M in Q3 2017.
350 funds tracked by Wall St. Rank held Avanos Medical as of Q4 2017.

Based on 361 Capital's 13F filing for Q4 2017, filed 14 Feb 2018.